

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Carmustine implants and temozolomide for the treatment of newly diagnosed glioblastoma multiforme

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Link Pharmaceuticals Ltd (carmustine implants) • Schering-Plough Ltd (temozolomide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain Tumour Foundation • CancerBACUP • Cancer Research UK • Cancer Voices • Long Term Medical Conditions Alliance • Macmillan Cancer Relief • Marie Curie Cancer Care • National Cancer Alliance • National Council for Hospice and Specialist Palliative Care Services • British Brain Tumour Association • UK Brain Tumour Society • Brain and Spine Foundation • Neurological Alliance • Samantha Dickson Research Trust • Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Oncological Association • British Oncology Pharmacy Association • British Psychosocial Oncology Society • National Hospital for Neurology & Neurosurgery 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • Brain & Central Nervous System Tumours Guideline Development Group • British National Formulary • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals Ltd (carmustine) • Cambridge Laboratories (procarbazine) • Clonmel Healthcare Ltd (vincristine) • Mayne Pharma plc (vincristine) • Medac UK (lomustine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute <p><u>Assessment team</u></p> <ul style="list-style-type: none"> • National Coordinating Centre for Health Technology Assessment • Peninsula Technology Assessment Group, University of Exeter

National Institute for Clinical Excellence
 Consultation on the draft scope for the appraisal of
Carmustine implants for the treatment of glioblastoma multiforme

<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians' Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Society of British Neurological Surgeons <p><u>Others</u></p> <ul style="list-style-type: none"> • Denbighshire Local Health Board • Department of Health • Gedling PCT • Welsh Assembly Government 	
--	--

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association).

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).